Roy Buchanan
Stock Analyst at JMP Securities
(3.93)
# 601
Out of 4,924 analysts
67
Total ratings
39.68%
Success rate
15.24%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $59 | $61.77 | -4.48% | 6 | Jun 30, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $3.37 | +315.43% | 2 | Jun 17, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $23 → $24 | $7.40 | +224.32% | 14 | Jun 3, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $5.47 | +82.82% | 9 | May 28, 2025 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $33 → $31 | $11.15 | +178.03% | 6 | May 7, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.06 | +88.68% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.48 | +1,116.22% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $57.28 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $1.62 | +146.91% | 3 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $0.80 | +1,640.00% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $70.91 | -53.46% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $24 → $7 | $0.92 | +660.95% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $3.41 | +46.63% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $674.90 | -33.62% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $12.06 | +32.73% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.62 | - | 2 | Feb 16, 2023 |
Cidara Therapeutics
Jun 30, 2025
Maintains: Market Outperform
Price Target: $59
Current: $61.77
Upside: -4.48%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $3.37
Upside: +315.43%
Enanta Pharmaceuticals
Jun 3, 2025
Maintains: Market Outperform
Price Target: $23 → $24
Current: $7.40
Upside: +224.32%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.47
Upside: +82.82%
Dynavax Technologies
May 7, 2025
Maintains: Market Outperform
Price Target: $33 → $31
Current: $11.15
Upside: +178.03%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.06
Upside: +88.68%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.48
Upside: +1,116.22%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $57.28
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $1.62
Upside: +146.91%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $0.80
Upside: +1,640.00%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $70.91
Upside: -53.46%
Nov 21, 2024
Maintains: Market Outperform
Price Target: $24 → $7
Current: $0.92
Upside: +660.95%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.41
Upside: +46.63%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $674.90
Upside: -33.62%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $12.06
Upside: +32.73%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.62
Upside: -